Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

The Impact of Infant Bacille Calmette-Guérin Vaccination on the Immunogenicity of Other Vaccines: A Randomized Exploratory Study.

Maytum A. et al, (2024), Pediatr Infect Dis J

Serum HCoV-spike specific antibodies do not protect against subsequent SARS-CoV-2 infection in children and adolescents.

Ratcliffe H. et al, (2023), iScience, 26

Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency Virus.

Fidler S. et al, (2023), Clin Infect Dis, 76, 201 - 209

Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial.

Shaw RH. et al, (2022), Lancet Respir Med, 10, 1049 - 1060

Community seroprevalence of SARS-CoV-2 in children and adolescents in England, 2019-2021.

Ratcliffe H. et al, (2022), Arch Dis Child

Impact of meningococcal ACWY conjugate vaccines on pharyngeal carriage in adolescents: evidence for herd protection from the UK MenACWY programme.

Carr JP. et al, (2022), Clin Microbiol Infect

An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females.

Marchevsky NG. et al, (2022), EBioMedicine, 81

Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV.

Ogbe A. et al, (2022), JCI Insight, 7

Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial.

Stuart ASV. et al, (2022), Lancet, 399, 36 - 49

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil

Clemens SAC. et al, (2021), Nature Communications, 12

Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection.

Feng S. et al, (2021), Nat Med, 27, 2032 - 2040

Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial.

Liu X. et al, (2021), Lancet, 398, 856 - 869

Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)

EWER K. et al, (2021), The Lancet

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm sub-study of a phase 2/3 clinical trial

EWER K. et al, (2021), Lancet HIV

Immunogenicity of the UK group B meningococcal vaccine (4CMenB) schedule against groups B and C meningococcal strains (Sched3): outcomes of a multicentre, open-label, randomised controlled trial.

Davis K. et al, (2021), Lancet Infect Dis, 21, 688 - 696

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial.

Emary KRW. et al, (2021), Lancet, 397, 1351 - 1362

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.

Voysey M. et al, (2021), Lancet, 397, 881 - 891

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

Ramasamy MN. et al, (2021), Lancet, 396, 1979 - 1993

Understanding the reactogenicity of 4CMenB vaccine: Comparison of a novel and conventional method of assessing post-immunisation fever and correlation with pre-release in vitro pyrogen testing.

Valente Pinto M. et al, (2020), Vaccine, 38, 7834 - 7841

Gene expression profiling reveals insights into infant immunological and febrile responses to group B meningococcal vaccine.

O'Connor D. et al, (2020), Mol Syst Biol, 16

Load More

Include forthcoming?